Last updated: March 2026
Letrozole (Femara) is the most potent aromatase inhibitor available — achieving 99%+ estradiol suppression at standard doses. Originally for breast cancer, it found off-label success in fertility treatment. Its power makes it easy to crash estrogen; use with precision and frequent labs.
Letrozole is a non-steroidal, reversible aromatase inhibitor with the highest binding affinity for aromatase among all AIs. This extreme potency is both its strength and its danger.
Letrozole has 10-20x higher aromatase binding affinity than anastrozole. At 2.5mg/day, it suppresses estradiol by 99%+. Even 0.5mg can dramatically lower E2. This potency is why it's often called the "nuclear option."
Despite its potency, letrozole is reversible — it binds competitively to aromatase. Stop the drug and enzyme activity returns. This differs from exemestane's permanent enzyme destruction.
By suppressing estrogen, letrozole triggers FSH release via negative feedback removal. In women with PCOS, this induces ovulation. In men, it raises testosterone and can improve sperm parameters in some cases.
Half-life of 2-4 days means letrozole accumulates with daily dosing. This allows for less frequent dosing (2-3x/week for TRT) but also means effects persist after stopping. Plan accordingly.
Data from breast cancer trials, fertility studies, and testosterone research.
Letrozole dosing for fertility, TRT, and extreme E2 situations.
| Protocol | Dose | Frequency | Notes |
|---|---|---|---|
| Female Fertility (PCOS) | 2.5-7.5mg | Days 3-7 of cycle | First-line ovulation induction. Start 2.5mg, increase if no response. |
| Male Fertility / T Boost | 2.5mg | 2-3x/week | Off-label. Raises T by suppressing E2 feedback. Monitor labs closely. |
| TRT E2 Control (rare) | 0.25-0.5mg | 2x/week | Usually overkill — anastrozole/exemestane preferred. For extreme aromatizers only. |
| Gyno Reversal Attempt | 2.5mg | Daily (short-term) | Some attempt to crash E2 to reverse early gyno. Extreme approach. SERMs better. |
| Breast Cancer (Reference) | 2.5mg | Daily | FDA-approved indication. 5 years continuous. |
How letrozole compares to other aromatase inhibitors.
Most potent. Long half-life. Fertility use. Easy to crash E2.
Most prescribed. Easier to titrate. TRT standard.
Suicidal/irreversible. No rebound. Better lipids. PCT favorite.
Important interactions when using letrozole.
Similar concern to anastrozole — letrozole may reduce tamoxifen effectiveness by lowering E2. If combining AI + SERM for PCT, exemestane is safer.
Both used for ovulation induction. Generally not combined. Letrozole often preferred first-line for PCOS; clomiphene as backup.
If using letrozole on TRT, start with very low doses (0.25mg). It's extremely potent and can easily crash E2. Monitor labs every 4-6 weeks.
Letrozole sometimes combined with gonadotropins for IVF protocols to reduce estrogen-related complications and improve outcomes.
Primary research supporting letrozole's clinical applications.
Letrozole monotherapy improved disease-free survival by 18% compared to tamoxifen monotherapy in postmenopausal ER+ breast cancer. Established letrozole's superiority in this setting.
PMID: 19920050 →Letrozole resulted in higher live-birth rates (27.5%) than clomiphene (19.1%) in women with PCOS. Now considered first-line for ovulation induction in PCOS.
PMID: 25006718 →Letrozole 2.5mg twice weekly increased testosterone from 248 to 525 ng/dL in obese hypogonadal men. LH and FSH also increased significantly.
PMID: 18426824 →Support supplements for AI users and fertility.
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
This page is for educational purposes only. It is not medical advice. Letrozole is a prescription medication. Use for fertility or testosterone optimization should be under physician supervision with regular monitoring. Off-label use carries additional risks.